Vector-based gene therapy (National Institutes of Health)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVector-based gene therapy (National Institutes of Health)
Drug Alias NameTIL cell gene therapy (IL-2)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-2 stimulantsTumor necrosis factor agonists
TargetsInterleukin-2Tumor necrosis factor
Therapy Area/IndicationsColonic NeoplasmsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsColonic NeoplasmsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A